Zobrazeno 1 - 10
of 21
pro vyhledávání: '"G P, KOLESNIKOV"'
Autor:
G. S. Kolesnikov
Publikováno v:
Вестник урологии, Vol 7, Iss 4, Pp 49-52 (2020)
A clinical case of treatment of a 19-year-old patient with hydrocele on the left, polyorchism is described. In 2012, a patient underwent surgery on the left for varicocele on the left. Hydrocele developed one year after Ivanissevich’s surgery on th
Externí odkaz:
https://doaj.org/article/97d9df30ad7e4d76882a19932216d668
Autor:
M. I. Volkova, A. S. Kalpinskiy, P. S. Borisov, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev, B. Ya. Alekseev, E. V. Peganova, A. F. Nasretdinov, E. V. Lymar, E. G. Ovchinnikova, T. A. Sveklina, E. A. Usynin, A. M. Abdelgafur, E. A. Tararova, L. M. Shumova, A. S. Belenkov, I. Yu. Dolgov, N. G. Ponomareva, I. V. Evstigneeva, A. N. Ivanov, A. R. Isaev, R. V. Leonenkov, A. V. Meskikh, M. R. Mukhitova, S. A. Orlova, I. V. Teslenok, M. M. Shegurova, M. T. Aivazov, Z. V. Amoev, K. G. Babina, A. A. Vorontsova, E. V. Karabina, N. V. Kirdakova, I. E. Shumskaya, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, E. S. Lyutova, M. M. Fael, A. N Chugarova, A. S. Antipin
Publikováno v:
Onkourologiâ, Vol 17, Iss 1, Pp 31-44 (2021)
Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91177b36520353fff8907e4b001ccdd
https://doi.org/10.17650/1726-9776-2021-17-1-31-44
https://doi.org/10.17650/1726-9776-2021-17-1-31-44
Autor:
G. I. Zaitsev, G. I. Kolesnikov
Publikováno v:
Вестник Кемеровского государственного университета, Vol 0, Iss 1-2, Pp 164-166 (2015)
The described laboratory work is devoted to studying one of modern optical elements – diffractive lens – at universities. The description of the work and guidance for its implementation are provided.
Externí odkaz:
https://doaj.org/article/49817ef7ab7c4e3b89177d7a0e174537
Autor:
V P Avdoshin, V E Rodoman, G P Kolesnikov, M I Andrukhin, O V Makarov, M N Israfilov, M N Annenkov, S A Pulbere, E V Ol'shanskaya
Publikováno v:
RUDN Journal of Medicine, Vol 0, Iss 3, Pp 103-107 (2011)
The estimation of efficacy of a medication «Trometamol-N» in complex therapy of urate and mixed urolithiasis, with application of extracorporeal shock wave lithotripsy (ESWL), low intensive laser irradiation is done. It was established that after s
Externí odkaz:
https://doaj.org/article/05800cf285d5444f9692eef86610b1c7
Autor:
M. I. Volkova, A. M. Abdelgafur, M. T. Aivazov, Z. V. Amoev, K. G. Babina, P. S. Borisov, A. A. Vorontsovа, I. V. Evstigneeva, O. I. Evsyukova, O. V. Zhelezin, A. S. Kalpinsky, E. V. Karabina, N. V. Kirdakova, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, R. V. Leonenkov, M. R. Maturov, A. V. Meskikh, S. V. Mishugin, E. G. Ovchinnikova, A. S. Olshanskaya, S. A. Protsenko, T. Yu. Semiglazova, R. V. Smirnov, E. A. Usynin, M. M. Fael, E. M. Cherniakova, I. E. Shumskaya
Publikováno v:
Onkourologiâ, Vol 15, Iss 3, Pp 56-69 (2019)
Objective: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy.Material. Russ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d301a22b53e5e52911c9452451cbb9
https://oncourology.abvpress.ru/oncur/article/view/984
https://oncourology.abvpress.ru/oncur/article/view/984
Autor:
B. Ya. Alekseev, A. D. Kaprin, G. P. Kolesnikov, A. A. Mukhomed’yarova, E. I. Konopleva, A. S. Kalpinskiy
Publikováno v:
Onkourologiâ, Vol 14, Iss 3, Pp 25-36 (2018)
Over the last 10 years, the capacities of second-line systemic therapy for metastatic renal cell carcinoma (mRCC) changed significantly. Targeted therapy is a standard treatment for patients with mRCC. However, the choice of therapeutic agents for su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5158b73cd2cff1cee050e368f0047eca
https://doi.org/10.17650/1726-9776-2018-14-3-25-36
https://doi.org/10.17650/1726-9776-2018-14-3-25-36
Publikováno v:
Onkourologiâ, Vol 12, Iss 3, Pp 96-101 (2016)
Castrate-resistant prostate cancer (CRPC) is one of the most complex and currently completely unsolved problems of oncourology. Possible novel treatment of CRPC is administration of Octreotide Long, long-acting somatostatin analogue. In this paper we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf39d8893f46934f7039b942d50ae34f
https://oncourology.abvpress.ru/oncur/article/view/614
https://oncourology.abvpress.ru/oncur/article/view/614
Publikováno v:
Onkourologiâ, Vol 12, Iss 3, Pp 30-39 (2016)
Background. This article is a personal experience of a sequential targeted therapy of tyrosine kinase inhibitors for the period from June 2005 to July 2015. Objective: evaluation of the results of the consistent application of targeted therapies in M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e2e0c58e5c600c5bad456f893d7f6bc
https://oncourology.abvpress.ru/oncur/article/view/563
https://oncourology.abvpress.ru/oncur/article/view/563
Autor:
V. I. Shirokorad, A. N. Makhson, I. G. Rusakov, G. P. Kolesnikov, S. V. Kostritskiy, K. Yu. Kashintsev, V. I. Borisov, M. I. Popov, M. Yu. Shchupak, N. V. Kirdakova, S. V. Mishugin, M. R. Maturov, A. G. Vinogradskiy, S. D. Shikhov, E. V. Gaydamaka, N. A. Apol’skaya, M. U. Shushakov, E. R. Babaev, A. A. Vorontsova, A. M. Ivanov, F. R. Amosov
Publikováno v:
Onkourologiâ, Vol 12, Iss 2, Pp 14-17 (2016)
The paper provides the first interim analysis of a database including information on 806 metastatic kidney cancer patients receiving targeted therapy in the cancer facilities of the Moscow Healthcare Department. It shows a comparative analysis of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3386b5b85bc3a2a341d9b34231934512
https://doi.org/10.17650/1726-9776-2016-12-2-14-17
https://doi.org/10.17650/1726-9776-2016-12-2-14-17
Autor:
M. I. Volkova, D. A. Nosov, V. A. Chernyaev, E. A. Voroshilova, M. S. Sayapina, G. P. Kolesnikov, R. V. Leonenkov, D. A. Khvorostenko, P. S. Borisov, M. U. Shushakov, N. V. Kirdakova, B. Ya. Alekseev, M. G. Matyash
Publikováno v:
Onkourologiâ, Vol 12, Iss 2, Pp 18-27 (2016)
Objective – to evaluate efficacy and safety of everolimus in Russian population of unselected patients with advanced renal cell carcinoma progressing after at least 1 line of anti-angiogenic targeted therapy. Materials and methods . In observationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db810ccf16c0143482dab0b7c3649e53
https://oncourology.abvpress.ru/oncur/article/view/571
https://oncourology.abvpress.ru/oncur/article/view/571